INT 131

Key Product Details

Product Description

INT 131 is a potent and selective PPARγ partial agonist (EC₅₀ = 4 nM; K_i = 3.7 nM). It has a 20-fold higher affinity for PPARγ compared with that of Rosiglitazone (Cat. No. 5325). INT 131 improves glucose tolerance in a rodent model of diabetes without inducing hemodynamic and cardiovascular effects. Antidiabetic agent.

Product Specifications for INT 131

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for INT 131

The following data is based on the product molecular weight 514.21.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.05 mM	38.89 mL	194.47 mL	388.95 mL
0.25 mM	7.78 mL	38.89 mL	77.79 mL
0.5 mM	3.89 mL	19.45 mL	38.89 mL
2.5 mM	0.78 mL	3.89 mL	7.78 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Motani INT131: a selective modulator of PPARγ. J.Mol.Biol. 2009 PMID: 19452630
• Frkic Structure-activity relationship of 2,4-Dichloro-N-(3,5-dichloro-4-(quinolin-3-yloxy)phenyl)benzenesulfonamide (INT131) analogs for PPARγ-targeted antidiabetics. J.Med.Chem. 2017 PMID: 28485590

Product Documents for INT 131